Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Declines By 14.7%
Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Declines By 14.7%
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,400 shares, a decrease of 14.7% from the March 31st total of 7,500 shares. Based on an average daily volume of 131,500 shares, the days-to-cover ratio is presently 0.0 days.
Pure Bioscience，Inc.(場外市場代碼：Pure-Get Rating)在4月份看到空頭股數的銷量大幅下降。截至4月15日，空頭股數共有6,400股，較3月31日的7,500股減少14.7%。以日均成交量131,500股計算，目前天數與回補比率為0.0天。
PURE Bioscience Price Performance
純生物科學性價比
Shares of PURE stock opened at $0.09 on Friday. The firm's 50-day moving average is $0.13 and its 200-day moving average is $0.14. PURE Bioscience has a 52-week low of $0.07 and a 52-week high of $0.24.
純股票週五開盤報0.09美元。該公司的50日移動均線切入位在0.13美元，200日移動均線切入位在0.14美元。Pure Bioscience的52周低點為0.07美元，52周高位為0.24美元。
PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its earnings results on Friday, March 17th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.40 million during the quarter. PURE Bioscience had a negative net margin of 228.72% and a negative return on equity of 142.15%.
Pure Bioscience(OTCMKTS：Pure-Get Rating)上一次發佈財報是在3月17日(星期五)。該公司公佈了該季度每股收益(EPS)(0.01美元)。該公司本季度的收入為40萬美元。純生物科學公司的淨利潤率為負228.72%，淨資產回報率為負142.15%。
Institutional Investors Weigh In On PURE Bioscience
機構投資者參與純生物科學
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC acquired a new position in shares of PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned about 0.92% of PURE Bioscience as of its most recent SEC filing. 0.92% of the stock is currently owned by institutional investors and hedge funds.
一家機構投資者最近買入了一隻新的純生物科學股票頭寸。根據IFG Consulting LLC最近提交給美國證券交易委員會(SEC)的13F檔案，該公司在第三季度收購了Pure Bioscience，Inc.(場外交易市場代碼：Pure-Get Rating)的股票。該公司收購了809,809股公司股票，價值約161,000美元。截至最近提交的美國證券交易委員會申請檔案，IFG Consulting LLC持有Pure Bioscience約0.92%的股份。該股目前由機構投資者和對沖基金持有0.92%。
PURE Bioscience Company Profile
Pure Bioscience公司簡介
(Get Rating)
(獲取評級)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Pure Bioscience，Inc.致力於發現、開發和商業化用於病原體和衛生控制的專有抗菌產品。它提供以檸檬酸二氫銀為基礎的消毒和消毒產品。該公司由Michael L.Krall於1992年8月24日創立，總部設在加利福尼亞州的蘭喬庫卡蒙加。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- 免費獲取StockNews.com關於純生物科學的研究報告(PURE)
- 市場回顧周-4/24-4/28
- 如何投資今年最受歡迎的食品雜貨股
- 陣列技術將太陽耀斑帶到2023年收益預測
- 利率上升前最適合投資的銀行股
- 如何投資農田：7個簡單的方法
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《純生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pure Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。